Cipla Q2 profit falls 35%, misses estimates
Cipla announced Q2 FY27 consolidated results on 27 October 2026. Revenue from operations fell 2.4% year on year to about ₹7,404 crore. EBITDA declined 26.7% to ₹1,388 crore, with the margin contracting 630 basis points to 18.7% from 25%. North America revenue fell 19% to $172 million. One India grew 12% to a quarterly high; South Africa private-market business grew about 1.3 times faster than the market; Emerging Markets and Europe posted $101 million. R&D was ₹423 crore, or 5.7% of sales. Net cash stood at ₹9,823 crore. Shares retreated from the day's high after the miss. Net profit figures diverge by outlet. The Economic Times reported ₹878 crore, down 35% from ₹1,351 crore and short of an LSEG estimate of ₹942 crore. Free Press Journal reported ₹851.51 crore, down 37.1%. CNBC-TV18 cited a miss versus its ₹949 crore poll and a Street revenue estimate of ₹7,498 crore; its poll had EBITDA at ₹1,371 crore and margin at 18.3%. Cipla said it expects North America performance to remain supported by its upcoming product pipeline. Achin Gupta said the company continues to focus on sustained growth in core businesses, improving productivity, and strengthening its pipeline to serve patients with trusted, high-quality medicines.




